Access to medication-assisted therapy for opioid overuse, and the use of telemedicine for provision of services (HR 4531, Support for Patients and Communities Reauthorization/ no Senate number yet )
Funding for programs to support substance abuse education and treatment (Labor-HHS Appropriations bill for Fy 2025/ mo bill number yet)
Medicaid Reentry Act - Legislation to allow Medicaid reimbursement for health care services 30 days prior to release from incarceration. HR 2400/ S. 1165).
Potential amendments to the Inflation Reduction Act dealing with policies for treatment of opioid overuse disorder.
Duration: November 6, 2017
to
June 1, 2024
General Issues: Alcohol & Drug Abuse , Budget/Appropriations , Medicare/Medicaid , Health Issues , Pharmacy
Spending: about $1,050,000 (But it's complicated. Here's why.)
It can be tricky to figure out how much an organization spent on a particular lobbying engagement. The law only requires lobbyists to report the amount they were paid for federal lobbying each quarter rounded to the nearest $10,000—and if it's less than $3,000 in a given quarter (or less than $13,000 for organizations with in-house lobbyists), they don't have to disclose it at all. Plus, some organizations include spending that doesn’t belong in the report—for instance, money spent lobbying state governments or other legal work.
Agencies lobbied since 2017: U.S. Senate, House of Representatives, Drug Enforcement Administration (DEA), Justice - Dept of (DOJ), Health & Human Services - Dept of (HHS)
Lobbyists
Lobbyists named here were listed on a filing related to this lobbying engagement. They may not be working on it now. Occasionally, a single lobbyist whose name is spelled two different ways on filings may be represented twice here.
Lobbyist
Covered positions?
Patricia Knight Chief of Staff, Senator Orrin G. Hatch; Health Policy Director, Senator Orrin G. Hatch.
Chief of Staff, Senator Orrin G. Hatch (1999-2007)
Disclosures Filed
Once a lobbying engagement begins, the lobbyist or firm is required to file updates four times a year. Those updates sometimes change which lobbyists are involved or add new issues being discussed. When lobbyists stop working for a client, the firm is also supposed to file a report disclosing the end of the relationship.
2nd Quarter, 2024
Knight Capitol Consultants terminated an engagement in which they represented Indivior, Inc. on May 30.
Original Filing: 301579895.xml
Lobbying Issues
Access to medication-assisted therapy for opioid overuse, and the use of telemedicine for provision of services (HR 4531, Support for Patients and Communities Reauthorization/ no Senate number yet )
Agencies Lobbied
U.S. Senate
Lobbying Issues
Funding for programs to support substance abuse education and treatment (Labor-HHS Appropriations bill for Fy 2025/ mo bill number yet)
Agencies Lobbied
U.S. House of Representatives
Lobbying Issues
Medicaid Reentry Act - Legislation to allow Medicaid reimbursement for health care services 30 days prior to release from incarceration. HR 2400/ S. 1165).
Agencies Lobbied
U.S. Senate
Lobbying Issues
Potential amendments to the Inflation Reduction Act dealing with policies for treatment of opioid overuse disorder.
Agencies Lobbied
U.S. Senate
1st Quarter, 2024
In Q1, Knight Capitol Consultants lobbied for Indivior, Inc. , earning $50,000. The report was filed on April 23.
Original Filing: 301577026.xml
Lobbying Issues
Access to medication-assisted therapy for opioid overuse, and the use of telemedicine for provision of services (HR 4531, Support for Patients and Communities Reauthorization/ no Senate number yet )
Agencies Lobbied
U.S. Senate
Lobbying Issues
Implementation of funding for programs to support substance abuse education and treatment (HR 4368, Labor-HHS Appropriations bill for Fy 2024/ S. 2624)
Agencies Lobbied
U.S. House of Representatives
Lobbying Issues
Medicaid Reentry Act - Legislation to allow Medicaid reimbursement for health care services 30 days prior to release from incarceration. HR 2400/ S. 1165).
Agencies Lobbied
U.S. Senate
Lobbying Issues
Potential amendments to the Inflation Reduction Act dealing with policies for treatment of opioid overuse disorder.
Agencies Lobbied
U.S. Senate
4th Quarter, 2023
In Q4, Knight Capitol Consultants lobbied for Indivior, Inc. , earning $50,000. The report was filed on Jan. 22.
Original Filing: 301541090.xml
Lobbying Issues
Access to medication-assisted therapy for opioid overuse, and the use of telemedicine for provision of services (HR 4531, Support for Patients and Communities Reauthorization/ no Senate number yet )
Agencies Lobbied
U.S. Senate
Lobbying Issues
Adequacy of funding for programs to support substance abuse education and treatment (HR 4368, Labor-HHS Appropriations bill for Fy 2024/ S. 2624)
Agencies Lobbied
U.S. House of Representatives
Lobbying Issues
Medicaid Reentry Act - Legislation to allow Medicaid reimbursement for health care services 30 days prior to release from incarceration. HR 2400/ S. 1165).
Agencies Lobbied
U.S. Senate
Lobbying Issues
Potential amendments to the Inflation Reduction Act dealing with policies for treatment of opioid overuse disorder.
Agencies Lobbied
U.S. Senate
3rd Quarter, 2023
In Q3, Knight Capitol Consultants lobbied for Indivior, Inc. , earning $50,000. The report was filed on Oct. 20, 2023.
Original Filing: 301515264.xml
Lobbying Issues
Access to medication-assisted therapy for opioid overuse, and the use of telemedicine for provision of services (HR 4531, Support for Patients and Communities Reauthorization/ no Senate number yet
Agencies Lobbied
U.S. Senate
Lobbying Issues
Adequacy of funding for programs to support substance abuse education and treatment (HR 4368, Labor-HHS Appropriations bill for Fy 2024/ S. 2624)
Agencies Lobbied
U.S. House of Representatives
Lobbying Issues
Medicaid Reentry Act - Legislation to allow Medicaid reimbursement for health care services 30 days prior to release from incarceration. HR 2400/ S. 1165).
Agencies Lobbied
U.S. Senate
Lobbying Issues
Potential amendments to the Inflation Reduction Act dealing with policies for treatment of opioid overuse disorder.
Agencies Lobbied
U.S. Senate
2nd Quarter, 2023
In Q2, Knight Capitol Consultants lobbied for Indivior, Inc. , earning $50,000. The report was filed on July 20, 2023.
Original Filing: 301491580.xml
Lobbying Issues
Access to medication-assisted therapy for opioid overuse, and the use of telemedicine for provision of services (HR 4531, Sipport for Patients and Communities Reauthorization)
Agencies Lobbied
U.S. Senate
Lobbying Issues
Adequacy of funding for programs to support substance abuse education and treatment (HR 4368, Labor-HHS Appropriations bill for Fy 2024)
Agencies Lobbied
U.S. House of Representatives
Lobbying Issues
Medicaid Reentry Act - successor legislation to last Congress' (S 1165/HR 2400) Legislation to allow Medicaid reimbursement for health care services 30 days prior to release from incarceration.
Agencies Lobbied
U.S. Senate
Lobbying Issues
Potential amendments to the Inflation Reduction Act dealing with pharmaceutical reimbursements.
Agencies Lobbied
U.S. Senate
1st Quarter, 2023
In Q1, Knight Capitol Consultants lobbied for Indivior, Inc. , earning $50,000. The report was filed on April 20, 2023.
Original Filing: 301465899.xml
Lobbying Issues
Access to medication-assisted therapy for opioid overuse, and the use of telemedicine for provision of services (no specific legislation yet)
Agencies Lobbied
U.S. Senate
Lobbying Issues
Adequacy of funding for programs to support substance abuse education and treatment (no legislation yet);
Agencies Lobbied
U.S. House of Representatives
Lobbying Issues
Medicaid Reentry Act - successor legislation to last Congress' H.R. 955/ S.285 (not introduced yet this quarter) Legislation to allow Medicaid reimbursement for health care services 30 days prior to release from incarceration.
Agencies Lobbied
U.S. Senate
Lobbying Issues
Potential amendments to the Inflation Reduction Act dealing with pharmaceutical reimbursements.
Agencies Lobbied
U.S. Senate
4th Quarter, 2022
In Q4, Knight Capitol Consultants lobbied for Indivior, Inc. , earning $40,000. The report was filed on Jan. 19, 2023.
Original Filing: 301435778.xml
Lobbying Issues
Mainstreaming Addiction Treatment Act ( HR 1384; S 445, PL 117-328, Consolidated Appropriations Act)); Medication Access and Training Expansion Act, (HR 2067, HR 7667, PL 117-328); Reducing Barriers to Substance use Training Act (no bill number in this Congress).
Agencies Lobbied
U.S. Senate
Lobbying Issues
Funding for mental health and substance abuse research and grants; issues related to regulation and pricing of pharmaceuticals in any FY 2023 Labor-HHS appropriations act or in the Consolidated Appropriations Act PL 117-328).
Agencies Lobbied
U.S. House of Representatives
Lobbying Issues
The Medicaid Re-entry Act (H.R. 955/S. 445); policies related to reimbursement of substance use disorder treatment (Restoring Hope for Mental Health and Well-Being Act, HR 7666). Possible changes in reimbursement for pharmaceuticals (HR 3, HR 5376 - Build Back Better Act, and any successor legislation, budget reconciliation legislation (no bill numbers)
Agencies Lobbied
U.S. Senate
Lobbying Issues
Mainstreaming Addiction Treatment Act (HR 2067, HR 7667); Drug Enforcement Administration regulation of buprenorphine under the Controlled Substances Act. Food and Drug Administration Safety and Landmark Advancement act FDASLA / FDA user fee reauthorization (HR 7667, S 4348, PL 117-70, Further Extending Government Funding Act) ; Restoring Hope for Mental Health and Well-Being Act (HR 7666); Medication Access and Training Expansion Act (HR 2067, S 2235; the Consolidated Appropriations Act PL 117-328).
Agencies Lobbied
U.S. Senate
3rd Quarter, 2022
In Q3, Knight Capitol Consultants lobbied for Indivior, Inc. , earning $40,000. The report was filed on Oct. 20, 2022.
Original Filing: 301413283.xml
Lobbying Issues
Mainstreaming Addiction Treatment Act ( HR 1384; S 445); Medication Access and Training Expansion Act, (HR 2067, HR 7667); Reducing Barriers to Substance use Training Act (no bill number in this Congress).
Agencies Lobbied
U.S. Senate
Lobbying Issues
Funding for mental health and substance abuse research and grants; issues related to regulation and pricing of pharmaceuticals in any FY 2023 Labor-HHS appropriations act or in the Further Extending Government Funding Act PL 117-70).
Agencies Lobbied
U.S. Senate
Lobbying Issues
The Medicaid Re-entry Act (H.R. 955/S. 445); policies related to reimbursement of substance use disorder treatment (Restoring Hope for Mental Health and Well-Being Act, HR 7666). Possible changes in reimbursement for pharmaceuticals (HR 3, HR 5376 - Build Back Better Act, and any successor legislation, budget reconciliation legislation (no bill numbers)
Agencies Lobbied
U.S. Senate
Lobbying Issues
Mainstreaming Addiction Treatment Act (HR 2067, HR 7667); Drug Enforcement Administration regulation of buprenorphine under the Controlled Substances Act. Food and Drug Administration Safety and Landmark Advancement act FDASLA / FDA user fee reauthorization (HR 7667, S 4348, PL 117-70, Further Extending Government Funding Act) ; Restoring Hope for Mental Health and Well-Being Act (HR 7666); Medication Access and Training Expansion Act (HR 2067, S 2235); the MOBILE Act, Maximizing Outcomes through Better Investment in Life Saving Equipment Act (PL 117-204).
Agencies Lobbied
U.S. Senate
2nd Quarter, 2022
In Q2, Knight Capitol Consultants lobbied for Indivior, Inc. , earning $40,000. The report was filed on July 20, 2022.
Original Filing: 301395307.xml
Lobbying Issues
Mainstreaming Addiction Treatment Act ( HR 1384; S 445); Medication Access and Training Expansion Act, (HR 2067, HR 7667);
Agencies Lobbied
U.S. Senate
Lobbying Issues
Funding for mental health and substance abuse research and grants; issues related to provisions affecting regulation and pricing of pharmaceuticals in any FY 2034 Labor-HHS appropriations act ( no bill yet)
Agencies Lobbied
U.S. Senate
Lobbying Issues
The Medicaid Re-entry Act (H.R. 955/S. 445); policies related to reimbursement of substance use disorder treatment (no specific legislation). Possible changes in reimbursement for pharmaceuticals (HR 3, HR 5376 - Build Back Better Act, and any successor legislation, budget reconciliation legislation ( no bill numbers)
Agencies Lobbied
U.S. Senate
Lobbying Issues
Implementation of section 3204 of the SUPPORT Act, PL 115-271; Mainstreaming Addiction Treatment Act (HR 2067, HR 7667); Drug Enforcement Administration regulation of buprenorphine under the Controlled Substances Act. Food and Drug Administration Safety and Landmark Advancement act FDASLA / FDA user fee reauthorization (HR 7667, S 4348; Restoring Hope for Mental Health and Well-Being Act (HR 7666).
Agencies Lobbied
U.S. Senate
1st Quarter, 2022
In Q1, Knight Capitol Consultants lobbied for Indivior, Inc. , earning $40,000. The report was filed on April 22, 2022.
Original Filing: 301373112.xml
Lobbying Issues
Adequacy of funding for state-based efforts to provide treatment for substance use disorders
Agencies Lobbied
U.S. Senate
Lobbying Issues
Funding for mental health and substance abuse research and grants; issues related to provisions affecting regulation and pricing of pharmaceuticals in the Build Back Better Act (H.R. 5376).
Agencies Lobbied
U.S. Senate
Lobbying Issues
The Medicaid Re-entry Act (H.R. 955/S. 445); policies related to reimbursement of substance use disorder treatment (no specific legislation). Possible changes in reimbursement for pharmaceuticals (HR 3, HR 5376 - Build Back Better Act, and any successor legislation)
Agencies Lobbied
U.S. Senate
Lobbying Issues
Implementation of section 3204 of the SUPPORT Act, PL 115-271; Mainstreaming Addiction Treatment Act (HR 2067); Medication Access and Training Expansion Act; (S 5000). Drug Enforcement Administration regulation of buprenorphine under the Controlled Substances Act.
Agencies Lobbied
U.S. Senate
4th Quarter, 2021
In Q4, Knight Capitol Consultants lobbied for Indivior, Inc. , earning $40,000. The report was filed on Jan. 18, 2022.
Original Filing: 301326387.xml
Lobbying Issues
Adequacy of funding for state-based efforts to provide treatment for substance use disorders (H.R. 4502/No Senate bill yet)
Agencies Lobbied
U.S. Senate
Lobbying Issues
Funding for mental health and substance abuse research and grants (H.R. 4502/no Senate bill yet); issues related to provisions affecting regulation and pricing of pharmaceuticals in the Build Back Better Act (H.R. 5376).
Agencies Lobbied
U.S. Senate
Lobbying Issues
The Medicaid Re-entry Act (H.R. 955/S. 445); policies related to reimbursement of substance use disorder treatment (no specific legislation). Possible changes in reimbursement for pharmaceuticals (HR 3, HR 5376 - Build Back Better Act, and any successor legislation)
Agencies Lobbied
U.S. Senate
Lobbying Issues
Implementation of section 3204 of the SUPPORT Act, PL 115-271; Mainstreaming Addiction Treatment Act (HR 2067); Medication Access and Training Expansion Act; (S 5000). Drug Enforcement Administration regulation of buprenorphine under the Controlled Substances Act.
Agencies Lobbied
U.S. Senate
3rd Quarter, 2021
In Q3, Knight Capitol Consultants lobbied for Indivior, Inc. , earning $40,000. The report was filed on Oct. 18, 2021.
Original Filing: 301302705.xml
Lobbying Issues
Adequacy of funding for state-based efforts to provide treatment for substance use disorders (H.R. 4502/No Senate bill yet)
Agencies Lobbied
U.S. Senate
Lobbying Issues
Funding for mental health and substance abuse research and grants (H.R. 4502/no Senate bill yet); issues related to provisions affecting regulation of pharmaceuticals in the Build Back Better Act (H.R. 5376).
Agencies Lobbied
U.S. Senate
Lobbying Issues
American Rescue Plan and funding for substance use disorder and mental health treatment (PL 117-2), the Medicaid Re-entry Act (H.R. 955/S. 445); policies related to reimbursement of substance use disorder treatment (no specific legislation). Possible changes in reimbursement for pharmaceuticals (HR 3 and any successor legislation)
Lobbying Issues
Implementation of section 3204 of the SUPPORT Act, PL 115-271; Mainstreaming Addiction Treatment Act (HR 2067); Medication Access and Training Expansion Act; (S 5000)
Agencies Lobbied
U.S. Senate
2nd Quarter, 2021
In Q2, Knight Capitol Consultants lobbied for Indivior, Inc. , earning $40,000. The report was filed on July 15, 2021.
Original Filing: 301276634.xml
Lobbying Issues
Adequacy of funding for state-based efforts to provide treatment for substance use disorders (bill not written yet)
Agencies Lobbied
U.S. Senate
Lobbying Issues
Funding for mental health and substance abuse research and grants (no specific bills yet); issues related to the budget reconciliation process.
Agencies Lobbied
U.S. Senate
Lobbying Issues
American Rescue Plan and funding for substance use disorder and mental health treatment (PL 117-2), the Medicaid Re-entry Act (H.R. 955/S. 445); policies related to reimbursement of substance use disorder treatment (no specific legislation). Possible changes in reimbursement for pharmaceuticals (HR 3 and any successor legislation)
Lobbying Issues
Implementation of section 3204 of the SUPPORT Act, PL 115-271
Agencies Lobbied
U.S. Senate
1st Quarter, 2021
In Q1, Knight Capitol Consultants lobbied for Indivior, Inc. , earning $40,000. The report was filed on April 20, 2021.
Original Filing: 301268223.xml
Lobbying Issues
Adequacy of funding for state-based efforts to provide treatment for substance use disorders (no specific legislation)
Agencies Lobbied
U.S. Senate
Lobbying Issues
Funding for mental health and substance abuse research and grants (no specific bills yet); issues related to the budget reconciliation process.
Agencies Lobbied
U.S. Senate
Lobbying Issues
American Rescue Plan and funding for substance use disorder and mental health treatment (PL 117-2), the Medicaid Re-entry Act (H.R. 955/S. 445); policies related to reimbursement of substance use disorder treatment (no specific legislation).
Lobbying Issues
Implementation of section 3204 of the SUPPORT Act, PL 115-271
Agencies Lobbied
U.S. Senate
4th Quarter, 2020
In Q4, Knight Capitol Consultants lobbied for Indivior, Inc. , earning $40,000. The report was filed on Jan. 25, 2021.
Original Filing: 301246713.xml
Lobbying Issues
Implementation of the Support for Patients and Communities Act (P.L. 115-271), including section 3204; funding levels and distribution of funding for treatment of opioid overuse disorder (OUD) (including any successor legislation to PL 116-123, Coronavirus Preparedness and Response Supplemental Appropriations Act; PL 116-127,Families First Coronavirus Response Act; PL 116-136, CARES Act; and HR 133, Consolidated Appropriations Act of 2021, PL 116-196.)
Agencies Lobbied
U.S. Senate
Lobbying Issues
Potential additional funding for opioid overuse treatment activities for FY 2020 (PL 116-196, Consolidated Appropriations Act of 2021).
Agencies Lobbied
U.S. Senate
Lobbying Issues
Omnibus legislation affecting prescription drug pricing (Senate HELP -Lower Healthcare Costs Act (S. 1895), Senate Finance - S. 2543, Prescription Drug Pricing Reduction Act (PDPRA) of 2019 and H.R. 3, Lower Drug Costs Now Act of 2019.
Lobbying Issues
DEA implementation of the SECURE Act and specifically Section 3204 addressing specialty pharmacy delivery providerS of long-acting injectable buprenorphine products. Fairness in Orphan Drug Exclusivity Act, H.R. 4712/S. 3271, included in H.R. 133, Consolidated Appropriations Act of 2021, PL 116-196).
Agencies Lobbied
U.S. Senate
3rd Quarter, 2020
In Q3, Knight Capitol Consultants lobbied for Indivior, Inc. , earning $40,000. The report was filed on Oct. 20, 2020.
Original Filing: 301224076.xml
Lobbying Issues
Implementation of the Support for Patients and Communities Act (P.L. 115-271), including section 3204; funding levels and distribution of funding for treatment of opioid overuse disorder (OUD) (including any successor legislation to PL 116-123, Coronavirus Preparedness and Response Supplemental Appropriations Act; PL 116-127,Families First Coronavirus Response Act; and PL 116-136, CARES Act.)
Agencies Lobbied
U.S. Senate
Lobbying Issues
Potential additional funding for opioid overuse treatment activities for FY 2020 (including H.R. 6800, HEROES Act, and any successor COVID-related bills to PL 116-123, Coronavirus Preparedness and Response Supplemental Appropriations Act; PL 116-127,Families First Coronavirus Response Act; and PL 116-136, CARES Act.)
Agencies Lobbied
U.S. Senate
Lobbying Issues
Omnibus legislation affecting prescription drug pricing (Senate HELP -Lower Healthcare Costs Act (S. 1895), Senate Finance - S. 2543, Prescription Drug Pricing Reduction Act (PDPRA) of 2019 and H.R. 3, Lower Drug Costs Now Act of 2019.
Lobbying Issues
DEA implementation of the SECURE Act and specifically Section 3204 addressing specialty pharmacy delivery to the provider of long-acting injectable buprenorphine products. Fairness in Orphan Drug Exclusivity Act, H.R. 4712/S. 3271.
Agencies Lobbied
U.S. Senate
2nd Quarter, 2020
In Q2, Knight Capitol Consultants lobbied for Indivior, Inc. , earning $40,000. The report was filed on July 18, 2020.
Original Filing: 301193359.xml
Lobbying Issues
Implementation of the Support for Patients and Communities Act (P.L. 115-271), including section 3204; funding levels and distribution of funding for treatment of opioid overuse disorder (OUD) (including any successor legislation to PL 116-123, Coronavirus Preparedness and Response Supplemental Appropriations Act; PL 116-127,Families First Coronavirus Response Act; and PL 116-136, CARES Act.)
Promote awareness of medication assisted treatment/treatment of OUD with long-acting injectable products (no specific legislation).
Agencies Lobbied
U.S. Senate
Lobbying Issues
Potential additional funding for opioid overuse treatment activities for FY 2020 (including H.R. 6800, HEROES Act, and any successor COVID-related bills to PL 116-123, Coronavirus Preparedness and Response Supplemental Appropriations Act; PL 116-127,Families First Coronavirus Response Act; and PL 116-136, CARES Act.)
Agencies Lobbied
U.S. Senate
Lobbying Issues
Omnibus legislation affecting prescription drug pricing (Senate HELP -Lower Healthcare Costs Act (S. 1895), Senate Finance - S. 2543, Prescription Drug Pricing Reduction Act (PDPRA) of 2019 and H.R. 3, Lower Drug Costs Now Act of 2019.
Lobbying Issues
DEA implementation of the SECURE Act and specifically Section 3204 addressing specialty pharmacy delivery to the provider of long-acting injectable buprenorphine products. Fairness in Orphan Drug Exclusivity Act, H.R. 4712/S. 3271.
Agencies Lobbied
U.S. Senate
1st Quarter, 2020
In Q1, Knight Capitol Consultants lobbied for Indivior, Inc. , earning $40,000. The report was filed on April 18, 2020.
Original Filing: 301172043.xml
Lobbying Issues
Implementation of the Support for Patients and Communities Act (P.L. 115-271), including section 3204; funding levels and distribution of funding for treatment of opioid overuse disorder (OUD) (including PL 116-123, Coronavirus Preparedness and Response Supplemental Appropriations Act; PL 116-127,Families First Coronavirus Response Act; and PL 116-136, CARES Act.)
Promote awareness of medication assisted treatment/treatment of OUD with long-acting injectable products (no specific legislation).
Agencies Lobbied
U.S. Senate
Lobbying Issues
Potential additional funding for opioid overuse treatment activities for FY 2020 (including PL 116-123, Coronavirus Preparedness and Response Supplemental Appropriations Act; PL 116-127,Families First Coronavirus Response Act; and PL 116-136, CARES Act.)
Agencies Lobbied
U.S. Senate
Lobbying Issues
Omnibus legislation affecting prescription drug pricing (Senate HELP -Lower Healthcare Costs Act (S. 1895), Senate Finance - S. 2543, Prescription Drug Pricing Reduction Act (PDPRA) of 2019 and H.R. 3, Lower Drug Costs Now Act of 2019.
Lobbying Issues
DEA implementation of the SECURE Act and specifically Section 3204 addressing specialty pharmacy delivery to the provider of long-acting injectable buprenorphine products. Fairness in Orphan Drug Exclusivity Act, H.R. 4712/S. 3271.
Agencies Lobbied
U.S. Senate
4th Quarter, 2019
In Q4, Knight Capitol Consultants lobbied for Indivior, Inc. , earning $30,000. The report was filed on Jan. 23, 2020.
Original Filing: 301130241.xml
Lobbying Issues
Implementation of the Support for Patients and Communities Act (P.L. 115-271); funding levels and distribution of funding for treatment of opioid overuse disorder (OUD) (Further Consolidated Appropriations Act, PL 116-94) promote awareness of medication assisted treatment/treatment of OUD with long-acting injectable products (no specific legislation).
Agencies Lobbied
U.S. Senate
Lobbying Issues
Funding for opioid overuse treatment activities for FY 2020 (Further Consolidated Appropriations Act PL 116-94)
Agencies Lobbied
U.S. Senate
Lobbying Issues
Omnibus legislation affecting prescription drug pricing (Senate HELP -Lower Healthcare Costs Act (S. 1895), Senate Finance - S. 2543, Prescription Drug Pricing Reduction Act (PDPRA) of 2019 and H.R. 3, Lower Drug Costs Now Act of 2019.
Lobbying Issues
DEA implementation of the SECURE Act and specifically Section 3204 addressing specialty pharmacy delivery to the provider of long-acting injectable buprenorphine products.
Agencies Lobbied
U.S. Senate
3rd Quarter, 2019
In Q3, Knight Capitol Consultants lobbied for Indivior, Inc. , earning $30,000. The report was filed on Oct. 21, 2019.
Original Filing: 301077962.xml
Lobbying Issues
Implementation of the Support for Patients and Communities Act (P.L. 115-271); funding levels and distribution of funding for treatment of opioid overuse disorder (OUD) (H.R. 2740);no Senate number yet) promote awareness of medication assisted treatment/treatment of OUD with long-acting injectable products.
Agencies Lobbied
U.S. Senate
Lobbying Issues
Funding for opioid overuse treatment activities for FY 2020 (H.R. 2740/no Senate bill number yet)
Agencies Lobbied
U.S. Senate
Lobbying Issues
Omnibus legislation affecting prescription drug pricing (Senate HELP -Lower Healthcare Costs Act (S. 1895), Senate Finance - S. 2543, Prescription Drug Pricing Reduction Act (PDPRA) of 2019 and H.R. 3, Lower Drug Costs Now Act of 2019. Provision related to Medicaid best price calculation in Public Law No: 116-59, FY 2020 Continuing Appropriations.
2nd Quarter, 2019
In Q2, Knight Capitol Consultants lobbied for Indivior, Inc. , earning $30,000. The report was filed on July 27, 2019.
Original Filing: 301060143.xml
Lobbying Issues
Implementation of the Support for Patients and Communities Act (P.L. 115-271); funding levels and distribution of funding for treatment of opioid overuse disorder (OUD) (H.R. 2740); promote awareness of medication assisted treatmennt/treatment of OUD with long-acting injectable products.
Agencies Lobbied
U.S. Senate
Lobbying Issues
Funding for opioid overuse treatment activities for FY 2020 (H.R. 2740/no Senate bill number yet)
Agencies Lobbied
U.S. Senate
Lobbying Issues
Omnibus legislation affecting prescription drug pricing (Senate HELP "Lower Healthcare Costs Act (S. 1895) and Finance bill (in development); H.R. 965, the Creating and Restoring Equal Access to Equivalent Samples (CREATES) Act of 2019; and
S. 102/H.R. 465, Prescription Drug Pricing Relief Act
1st Quarter, 2019
In Q1, Knight Capitol Consultants lobbied for Indivior, Inc. , earning $30,000. The report was filed on April 17, 2019.
Original Filing: 301027745.xml
Lobbying Issues
Implementation of the Support for Patients and Communities Act (P.L. 115-271)
Agencies Lobbied
U.S. Senate
Lobbying Issues
Funding for opioid overuse treatment activities for FY 2020 (no specific legislation)
Agencies Lobbied
U.S. Senate
Lobbying Issues
H.R. 2021, Investing for the People Act of 2019, budget legislation, potential provisions relating to prescription drug pricing, reporting and oversight.
H.R. 2113, the Prescription Drug Sunshine, Transparency, Accountability and Reporting Act or Prescription Drug STAR Act, provisions relating to prescription drug pricing, reporting and oversight requirements.
H.R. 938, the Bringing Low-cost Options and Competition while Keeping Incentives for New Generics (BLOCKING) Act of 2019, provisions relating to patent exclusivity.
H.R. 1503, the Orange Book Transparency Act of 2019, provisions to ensure that the Orange Book is accurate and up-to-date;
Omnibus legislation affecting prescription drug pricing (Senate HELP and Finance bills in development); H.R. 965, the Creating and Restoring Equal Access to Equivalent Samples (CREATES) Act of 2019; and
S. 102/H.R. 465, Prescription Drug Pricing Relief Act
Agencies Lobbied
U.S. Senate
4th Quarter, 2018
In Q4, Knight Capitol Consultants lobbied for Indivior, Inc. , earning $50,000. The report was filed on Jan. 17, 2019.
Original Filing: 301007482.xml
Lobbying Issues
Substance Use-Disorder Prevention that Promotes Opioid Recovery and Treatment for Patients and Communities Act or the SUPPORT for Patients and Communities Act - issues related to Medication-Assisted Therapy. (P.L. 115-271)
Agencies Lobbied
U.S. Senate
Lobbying Issues
Implementation of funding for opioid overuse disorder treatment in FY 2019 Labor-HHS Appropriations bills (PL 115-245)
Lobbying Issues
Ensuring Patient Access to Substance Use Disorder Treatments Act of 2018 (Section 3204 of the SUPPORT Act, P.L. 115-271)
Agencies Lobbied
U.S. Senate
3rd Quarter, 2018
In Q3, Knight Capitol Consultants lobbied for Indivior, Inc. , earning $30,000. The report was filed on Oct. 22, 2018.
Original Filing: 300994358.xml
Lobbying Issues
H.R. 6, Substance Use-Disorder Prevention that Promotes Opioid Recovery and Treatment for Patients and Communities Act or the SUPPORT for Patients and Communities Act - issues related to Medication-Assisted Therapy.
Agencies Lobbied
U.S. Senate
Lobbying Issues
Funding for opioid overuse disorder treatment in FY 2019 Labor-HHS Appropriations bills (HR 6157/PL 115-245)
Agencies Lobbied
U.S. Senate
Lobbying Issues
Ensuring Patient Access to Substance Use Disorder Treatments Act of 2018 (H.R. 5202/S.916/H.R. 6).
Agencies Lobbied
U.S. Senate
2nd Quarter, 2018
In Q2, Knight Capitol Consultants lobbied for Indivior, Inc. , earning $30,000. The report was filed on July 19, 2018.
Original Filing: 300971552.xml
Lobbying Issues
CARA 2.0 Act (S. 2456) and treatment of Medication-Assisted Therapy
Agencies Lobbied
U.S. Senate
Lobbying Issues
SAMHSA funding for opioid overuse disorder treatment in FY 2019 Labor-HHS Appropriations bills (no bill number)
Agencies Lobbied
U.S. Senate
Lobbying Issues
Ensuring Patient Access to Substance Use Disorder Treatments Act of 2018 (H.R. 5202/S.916); Opioid Crisis Response Act of 2018 (S.2680) provisions related to Medication Assisted Therapy.
Agencies Lobbied
U.S. Senate
1st Quarter, 2018
In Q1, Knight Capitol Consultants lobbied for Indivior, Inc. , earning $30,000. The report was filed on April 19, 2018.
Original Filing: 300949625.xml
Lobbying Issues
CARA 2.0 Act (S. 2456) and treatment of Medication-Assisted Therapy
Agencies Lobbied
U.S. Senate
Lobbying Issues
Provisions addressing medication assisted therapy included in the Consolidated Appropriations Act (PL 115-141).
Agencies Lobbied
U.S. Senate
Lobbying Issues
H.R. 5202/S. 916 Section 3: Ensuring Patient Access to Substance Use Disorder Treatments Act of 2018
Agencies Lobbied
U.S. Senate
4th Quarter, 2017
Knight Capitol Consultants amended a lobbying report for representation of Indivior, Inc. in Q42017 on Jan. 22, 2018.
Original Filing: 300936246.xml
Lobbying Issues
Possible development of Comprehensive Addiction and Recovery Act legislation ("CARA 2.0").
Agencies Lobbied
U.S. Senate
Lobbying Issues
Adequacy of funding for the National Institutes of Health, the Substance Abuse and Mental Health Administration, and for comprehensive efforts to prevent and treat opioid overuse through medication assisted treatment (HJRes 73; HR 1370).
Agencies Lobbied
U.S. Senate
Lobbying Issues
Distribution of practitioner-administered controlled substances under the Controlled Substances Act (Section 3 of S. 916).
Agencies Lobbied
U.S. Senate
4th Quarter, 2017
In Q4, Knight Capitol Consultants lobbied for Indivior, Inc. , earning $30,000. The report was filed on Jan. 22, 2018.
Original Filing: 300934308.xml
Lobbying Issues
Possible development of Comprehensive Addiction and Recovery Act legislation ("CARA 2.0").
Agencies Lobbied
U.S. Senate
Lobbying Issues
Adequacy of funding for the National Institutes of Health, the Substance Abuse and Mental Health Administration, and for comprehensive efforts to prevent and treat opioid overuse through medication assisted treatment (HJRes 73; HR 1370).
Agencies Lobbied
U.S. Senate
Lobbying Issues
Distribution of practitioner-administered controlled substances under the Controlled Substances Act (Section 3 of S. 916).
Agencies Lobbied
U.S. Senate
4th Quarter, 2017
Knight Capitol Consultants filed a lobbying registration on Dec. 22, 2017 to represent Indivior, Inc., effective Nov. 6, 2017.
Original Filing: 300920729.xml
Issue(s) they said they’d lobby about: Issues related to opioid addiction and treatment, including funding, research, and reimbursement; delivery of controlled substances to physicians (S. 916); implementation of the CARA law and possible development of CARA 2.0 .
Source: Clerk of the U.S. House of Representatives and Secretary of the Senate
Searching...